These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11195540)

  • 1. [The possibility of the use of several clinical, genetic and MRI characteristics for the prognosis of effects of beta-interferon-1beta treatment in multiple sclerosis].
    Boĭko AN; Khachanova NV; Buglak AV; Demina TL; Beliaeva IA; Lashch NV; Serkov SV; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2000; 100(12):53-9. PubMed ID: 11195540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Multiple sclerosis with early onset: pathogenesis, clinical characteristics, possibilities in the treatment of its pathogenesis].
    Maslova OI; Bykova OV; Guseva MR; Sidorenko EI; Boĭko SIu; Sudomoina MV; Studenikin VM; Shchelkovskiĭ VI; Favorova OO
    Zh Nevrol Psikhiatr Im S S Korsakova; 2002; Suppl():46-51. PubMed ID: 12418392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b.
    Fitzgerald KC; Munger KL; Köchert K; Arnason BG; Comi G; Cook S; Goodin DS; Filippi M; Hartung HP; Jeffery DR; O'Connor P; Suarez G; Sandbrink R; Kappos L; Pohl C; Ascherio A
    JAMA Neurol; 2015 Dec; 72(12):1458-65. PubMed ID: 26458124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Multiple sclerosis in children and adolescents: history and current experience of immunomodulating treatment].
    Bykova OV; Maslova OI; Guseva MR; Boĭko SIu; Totolian NA; Matveeva TA; Boĭko AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2004; 104(4):4-10. PubMed ID: 15270293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Betaferon--first experience of application in treatment of multiple sclerosis in Russia].
    Zavalishin IA; Iakhno NN; Zhuchenko TD; Niiazbekova AS
    Zh Nevrol Psikhiatr Im S S Korsakova; 1997; 97(12):24-7. PubMed ID: 9591060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The interferon beta therapy after the first clinical episode of demyelination in multiple sclerosis].
    Demina TL; Khachanova NV; Davydovskaia MV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(3):15-9. PubMed ID: 16608106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HLA-DRB1 does not have a role in clinical response to interferon-beta among Iranian multiple sclerosis patients.
    Samadzadeh S; Tabibian E; Sabokbar T; Shakoori A; Dehgolan SR; Armaki SA; Aslanbeigi B; Abolfazli R
    J Neurol Sci; 2015 May; 352(1-2):37-40. PubMed ID: 25824849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial.
    Comi G; De Stefano N; Freedman MS; Barkhof F; Polman CH; Uitdehaag BM; Casset-Semanaz F; Hennessy B; Moraga MS; Rocak S; Stubinski B; Kappos L
    Lancet Neurol; 2012 Jan; 11(1):33-41. PubMed ID: 22146409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A short history of beta-interferon therapy of multiple sclerosis].
    Stock G; Horowski R
    Med Klin (Munich); 2001 Sep; 96 Suppl 1():3-9. PubMed ID: 11603113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The use of beta-interferon-1b in children and adolescents with multiple sclerosis].
    Bykova OV; Kuzenkova LM; Maslova OI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(9):29-33. PubMed ID: 17069059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The results of longitudinal use of copaxone and betaferon in Moscow Multiple Sclerosis Center: issues of efficacy and adherence to therapy].
    Boĭko AN; Davydovskaia MF; Demina TL; Lashch NIu; Ovcharov VV; Popova NF; Sinbukhova NI; Khachanova NV; Shchur SG; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; Spec No 3():101-10. PubMed ID: 17172244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort.
    Kalincik T; Horakova D; Dolezal O; Krasensky J; Vaneckova M; Seidl Z; Havrdova E
    Clin Neurol Neurosurg; 2012 Sep; 114(7):940-6. PubMed ID: 22402204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination.
    Warabi Y; Matsumoto Y; Hayashi H
    J Neurol Sci; 2007 Jan; 252(1):57-61. PubMed ID: 17125797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment with beta-interferon should be started already after the first attack of MS].
    Söderström M
    Lakartidningen; 2001 Feb; 98(6):587-90, 593-4. PubMed ID: 11475246
    [No Abstract]   [Full Text] [Related]  

  • 16. The use of interferon beta in relapsing-remitting multiple sclerosis.
    Etheridge LJ; Beverley DW; Ferrie C; McManus E
    Arch Dis Child; 2004 Aug; 89(8):789-91. PubMed ID: 15269086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The importance of early diagnosis of multiple sclerosis.
    Miller JR
    J Manag Care Pharm; 2004 Jun; 10(3 Suppl B):S4-11. PubMed ID: 15253684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
    Cadavid D; Wolansky LJ; Skurnick J; Lincoln J; Cheriyan J; Szczepanowski K; Kamin SS; Pachner AR; Halper J; Cook SD
    Neurology; 2009 Jun; 72(23):1976-83. PubMed ID: 19279320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Experience in the treatment of multiple sclerosis with interferon beta in Galicia].
    Romero-López J; Seijo-Martínez M; Del Campo V; Amigo-Jorrín MC; Arias M; Cortés-Laíño JA; Dapena-Bolaño D; López-González FJ; Lorenzo-González JR; Marín-Sánchez M; Muñoz-García D; Ozaita-Arteche G; Prieto JM
    Rev Neurol; 2003 Dec 1-15; 37(11):1001-4. PubMed ID: 14669137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Certain problems of therapy with beta-interferon preparations].
    Gusev EI; Demina TL; Boĭko AN; Khachanova NV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2003; (Spec No 2):98-102. PubMed ID: 12938643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.